MDT · Full Picture

Medtronic plc — the full picture

Earnings window · 2026-06-18 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 87
    +25.4% revenue (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); structured_verified
    Q1 FY27 revenue: $9.8 billion, increased 13.7% as reported and 13.7% organic
  2. Guidance / Outlook · Guidance & outlookPriority 74
    +6.4% revenue; 2 sources (news, press_release); 6 forward row(s); quote_verified
    Medtronic's FY 2027 guidance targets 6.75%–7.25% organic revenue growth and $5.90–$6.00 non-GAAP EPS.
  3. Liquidity and Debt Position · Debt, leverage & refinancingPriority 68
    -7.2% liability; 5 forward row(s); structured_verified
    Contractual interest payments on Medtronic plc's outstanding debt, excluding debt premium and discount amortization, required on long-term debt outstanding at April 24, 2026 are projected to be $7.9 billion.
  4. Gross Margin Drivers · Gross marginPriority 61
    -4.1% operating_income (realized); 3 sources (news, press_release, sec_filing); structured_verified
    Q1 GAAP net income: $1,470 million and GAAP diluted EPS: $1.14, increases of 41.4% and 40.7% respectively
  5. Cardiovascular Product Growth · UnclassifiedPriority 60
    +4.1% revenue (realized); 2 sources (news, sec_filing); 3 forward row(s); structured_verified
    GlobeNewswire/BCC Research projects the global cardiovascular devices market will grow from $72.4 billion in 2025 to $101.6 billion by 2030 and names Medtronic as a major player.
  6. Diabetes Business Separation · UnclassifiedPriority 59
    3 sources (news, press_release, sec_filing); 4 forward row(s); quote_verified
    Medtronic plans to complete the separation of its Diabetes Business within this fiscal year (fiscal year 2027).
  7. Goodwill Impairment Risk · Restructuring & impairmentPriority 58
    quote_verified
    If the discount rate was to increase 1%, the approximate percentage by which the fair value exceeds the carrying value would range from 3% to 307%.
  8. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 55
    +0.4% assets; 3 sources (news, press_release, sec_filing); 13 forward row(s); structured_verified
    Company completed acquisitions of Scientia Vascular and SPR Therapeutics, Inc.
  9. Free Cash Flow · Cash flow generationPriority 55
    +2.1% cash (realized); 3 sources (news, press_release, sec_filing); structured_verified
    Medtronic reported free cash flow of $4.63 billion.
  10. Geographic Market Commentary · Geographic mixPriority 54
    2 sources (press_release, sec_filing); quote_verified
    Medtronic employs a global team of 95,000+ people across more than 150 countries
  11. Dividend Declaration · Buybacks & dividendsPriority 51
    2 forward row(s); quote_verified
    Medtronic announced a quarterly dividend of $0.72 per share.
  12. Market Demand Trends · Demand, orders & backlogPriority 51
    2 sources (news, press_release); quote_verified
    Fox Run Management L.L.C. significantly increased its stake in Medtronic PLC by 364.9% in the second quarter, bringing its total holdings to 23,397 shares valued at $1.83 million.

Threads by pillar

Revenue & Demand Priority 94 · 10 threads

Costs & Margins Priority 76 · 6 threads

Capital & Balance Sheet Priority 85 · 8 threads

Strategy & Portfolio Priority 76 · 10 threads

Legal, Regulatory & Policy Priority 53 · 4 threads

Guidance & Outlook Priority 74 · 1 thread

Macro & Market Conditions Priority 47 · 3 threads

Management & Governance Priority 31 · 2 threads

Unclassified Priority 91 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
liability-8.7%+8.7%-4.1%
revenue+6.4%+6.4%+31.7%
cash-2.3%+2.3%-1.8%
net_income-1.7%+1.7%-1.5%
assets+1.4%+1.4%-0.4%
operating_income-0.3%+0.3%-8.8%
margin——+0.1%